anti-CD19 CAR T-cell therapy (Precigen/ZIOPHARM)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Precigen/ZIOPHARM)
Drug Alias Namesecond-generation anti-CD19 CAR T-cell therapy (Intrexon/ZIOPHARM)second-generation non-viral adoptive CAR T-cell therapy (Intrexon/ZIOPHARM)non-viral adoptive CAR T-cell therapies (Intrexon/ZIOPHARM)anti-CD19 CAR T-cell therapy (Intrexon/ZIOPHARM)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesAlaunos Therapeutics IncPrecigen Inc
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A